Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for ProTmune for Prevention of Acute GvHD and CMV Infection
January 26, 2016 16:36 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Jan. 26, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for cancer...
China Food and Drug Administration Accepts IND for Pivotal Study of AMITIZA(R) (lubiprostone)
June 15, 2015 16:02 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., June 15, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global pharmaceutical company, today announced that the China Food and Drug Administration...
FDA Grants Fast Track Designation to Sucampo's Cobiprostone for Oral Mucositis
May 07, 2015 16:42 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., May 7, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA)...
FDA Authorizes New Hemispherx Biopharma Clinical Trial of Intranasal Ampligen(R) With Seasonal Influenza Vaccine
July 20, 2011 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 20, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") today announced it has received U.S. Food Drug Administration (FDA)...